AstraZeneca PLC Ordinary Shares (AZN)

R&D Expenses

$4.05B

Quarterly · Period ending: · USD

AZN logo

AZN R&D Expenses

Latest reported$4.05B
AZN Quarterly R&D Expenses ($0.00 → $4.05B)
High-resolution chart · PNG

AZN r&d expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

AstraZeneca PLC Ordinary Shares R&D Expenses — Quarterly (USD)
Period endingR&D Expenses (USD)
4,053,000,000
3,492,000,000
3,862,000,000
3,663,000,000
3,548,000,000
3,159,000,000
4,677,000,000
3,115,000,000
3,008,000,000
2,783,000,000
3,073,000,000
2,584,000,000
2,667,000,000
2,611,000,000
2,788,000,000
2,458,000,000
2,546,000,000
2,133,000,000
4,145,000,000
3,610,000,000
1,829,000,000
1,713,000,000
2,048,000,000
1,495,000,000
1,389,000,000
1,388,000,000
2,173,000,000
1,346,000,000
1,356,000,000
1,266,000,000
2,012,000,000
1,242,000,000
1,362,000,000
1,279,000,000
1,551,000,000
1,404,000,000
1,349,000,000
1,453,000,000
1,543,000,000
1,402,000,000
1,465,000,000
1,480,000,000
1,746,000,000
1,429,000,000
1,466,000,000
1,356,000,000
1,499,000,000
1,552,000,000
1,328,000,000
1,200,000,000
1,429,000,000
858,000,000
1,275,000,000
1,259,000,000
1,320,000,000
1,204,000,000
1,189,000,000
1,530,000,000
1,867,000,000
1,296,000,000
1,198,000,000
1,162,000,000
1,930,000,000
1,077,000,000
1,320,000,000
991,000,000
1,314,000,000
1,056,000,000
1,059,000,000
980,000,000
1,471,000,000
1,261,000,000
1,265,000,000
1,182,000,000
1,469,000,000
1,327,000,000
1,196,000,000
1,170,000,000
1,124,000,000
962,000,000
955,000,000
861,000,000
873,000,000
781,000,000
860,000,000
865,000,000
1,235,000,000
823,000,000
888,000,000
857,000,000
1,042,000,000
807,550,220
818,159,986
783,289,792
896,783,771
744,120,891
723,000,000
697,000,000
2,006,402,577
614,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.